Abstract:Background Cisplatin has proved itself an effective therapeutic approach in a variety of solid tumors. However, its therapeutic concentration was limited since the presence of variant inevitable side effects. Nanoparticles (NPs) developed from amphiphilic copolymers have drawn great attention for prolonging drug residency in blood circulation, increasing tumor accumulation, reducing serum protein adherence and preventing uptake by the reticuloendothelial system (RES). Previously, we synthesized polyethylene glycol (PEG)- polycaprolactone (PCL) NPs as anticancer drug and had confirmed its efficacy in vitro. To comprehensively study the influences of cisplatin-loaded PEG-PCL copolymeric NPs, we enlarge the amount of murine models and applied more physical tests to offer a broader view of the impact that cisplatin-loaded PEG-PCL copolymeric NPs brought about. Methods We observed the physical alteration of hepatoma-bearing mice and the tumors after administration of cisplatin-loaded PEG-PCL nanoparticles (NPs). Cell uptake and apoptotic rates were measured through fluorescence microscopy and flowcytometry. Murine blood was collected and examined. Positron emission tomography/computed tomography (PET/CT) was utilized for the detection of tumor metabolic status. Results The biopsy and the measurement of tumor volume and murine weights have confirmed the therapeutic efficacy of cisplatin-loaded NPs and was positively related to the dosage of cisplatin. Fluorescence microscope images indicated a better cellular uptake rate of cisplatin-loaded NPs with intracellularly-aggregated, heterogeneous rhodamine B observed in LoVo cells. A decline of apoptotic rates in cisplatin-loaded NPs was measured. Blood tests exhibited less side effects in cisplatin-loaded NPs with higher level of white blood cells and lower aspartate transaminase (AST). PET/CT images revealed less intensity of FDG uptake in murine received higher dosage of cisplatin-loaded NPs. Conclusions Nanoparticles prepared from PEG-PCL/PCL hybrids could be a promising drug carrier for intratumoral delivery with greater efficacy and less side effects. This study provides a theoretical basis for possible clinical application. Legal entity responsible for the study Comprehensive Cancer Center of Drum-Tower Hospital Comprehensive Cancer Center of Drum-Tower Hospital Comprehensive Cancer Center of Drum-Tower Hospital. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Oridonin-loaded poly(ε-caprolactone)–poly(ethylene oxide)–poly(ε-caprolactone) copolymer nanoparticles: Preparation, characterization, and antitumor activity on mice with transplanted hepatoma

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

Preparation and Characterization of Oridonin-loaded Poly (caprolactone)-Poly (ethylene oxide)-Poly (caprolactone) Copolymer Nanoparticles

Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway

Galactosylated Chitosan Nanoparticles for Hepatocyte-Targeted Delivery of Oridonin

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

Oridonin Nanosuspension Enhances Anti-Tumor Efficacy in SMMC-7721 Cells and H22 Tumor Bearing Mice

In Vivo Evaluation of Cisplatin-Loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery

A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment

Fabrication of doxorubicin conjugated methoxy poly(ethylene glycol)-block-poly(ε-caprolactone) nanoparticles and study on their in vitro antitumor activities

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Synergistic combination therapy of lung cancer using lipid-layered cisplatin and oridonin co-encapsulated nanoparticles

Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice.

Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates.

Paclitaxel-loaded Poly(n-Vinylpyrrolidone)-b-poly(ε-caprolactone) Nanoparticles: Preparation and Antitumor Activity in Vivo

In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers

In Vitro and in Vivo Antitumor Activity of Oridonin Nanosuspension

Oleanolic Acid-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles for Enhancing Chemotherapy to Liver Cancer.

Novel co-delivery of oridonin and docetaxel nanoliposome for an enhanced antitumor effect on esophageal cancer

Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin

Prominent Enhancement of Cisplatin Efficacy with Optimized Methoxy Poly(ethylene Glycol)-Polycaprolactone Block Copolymeric Nanoparticles.